Rivaroxaban treatment for young patients with pulmonary embolism (Review)
- Authors:
- Haidi Wu
- Hongyan Cao
- Zikai Song
- Xiaoyan Xu
- Minglong Tang
- Shuo Yang
- Yang Liu
- Ling Qin
-
Affiliations: Department of Cardiology, The First Hospital of Jilin University, Changchun, Jilin 130000, P.R. China - Published online on: May 25, 2020 https://doi.org/10.3892/etm.2020.8791
- Pages: 694-704
-
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Tritschler T, Kraaijpoel N, Le Gal G and Wells PS: Venous thromboembolism: Advances in diagnosis and treatment. JAMA. 320:1583–1594. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Heit JA: Epidemiology of venous thromboembolism. Nat Rev Cardiol. 12:464–474. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Bartholomew JR: Update on the management of venous thromboembolism. Cleve Clin J Med. 84:39–46. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD and Anderson FA Jr: The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 154:861–866. 1994.PubMed/NCBI | |
|
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM and Melton LJ III: Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25 year population-based study. Arch Intern Med. 158:585–593. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Kumasaka N, Sakuma M and Shirato K: Clinical features and predictors of in-hospital mortality in patients with acute and chronic pulmonary thromboembolism. Intern Med. 39:1038–1043. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Kiluk IE, Krajewska A, Kosacka U, Tycińska A, Milewski R, Musiał W and Sobkowicz B: Different manifestations of pulmonary embolism in younger compared to older patients: Clinical presentation, prediction rules and long-term outcomes. Adv Med Sci. 62:254–258. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Jaquet E, Tritschler T, Stalder O, Limacher A, Méan M, Rodondi N and Aujesky D: Prediction of short-term prognosis in elderly patients with acute pulmonary embolism: Validation of the RIETE score. J Thromb Haemost. 16:1313–1320. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Engbers MJ, van Hylckama Vlieg A and Rosendaal FR: Venous thrombosis in the elderly: Incidence, risk factors and risk groups. J Thromb Haemost. 8:2105–2112. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gallus A, Jackaman J, Tillett J, Mills W and Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 2:1293–1296. 1986.PubMed/NCBI View Article : Google Scholar | |
|
Lotke PA and Ecker ML: Low-Molecular-weight heparin vs. Warfarin for prophylaxis against deep-vein thrombosis. N Engl J Med. 330(863)1994.PubMed/NCBI View Article : Google Scholar | |
|
Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S and Segers A: Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT dose-ranging study. Blood. 112:2242–2247. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Scaglione F: New oral anticoagulants: Comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 52:69–82. 2013.PubMed/NCBI View Article : Google Scholar | |
|
EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, et al: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 363:2499–2510. 2010.PubMed/NCBI View Article : Google Scholar | |
|
EINSTEIN–PE Investigators. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, et al: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 366:1287–1297. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al: Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 149:315–352. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, et al: 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35:3033–3069. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MPA, Büller HR, Elias A, Farge D, et al: Diagnosis and management of acute deep vein thrombosis: A joint consensus document from the European society of cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 39:4208–4218. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, Ying K, Liu C, Shao Y, Jing Z, et al: Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: A subgroup analysis of the EINSTEIN DVT and PE studies. Thromb J. 11(25)2013.PubMed/NCBI View Article : Google Scholar | |
|
Zhou Q, Wu Y, Jiang X, Liu X, Lei H, Jing Z and Huang W: [Efficacy comparison of 3 rivaroxaban regimen in patients with venous thromboembolism]. Zhonghua Xin Xue Guan Bing Za Zhi. 43:782–784. 2015.PubMed/NCBI | |
|
Song Z, Wu H, Cao H, Tang M, Yang S and Qin L: Nephrotic syndrome with acute pulmonary embolism in young adults: Two case reports. Medicine (Baltimore). 97(e11495)2018.PubMed/NCBI View Article : Google Scholar | |
|
Jara-Palomares L, Sanchez-Oro-Gomez R, Elias-Hernandez T, Morillo-Guerrero R, Ferrer-Galvan M, Asensio-Cruz MI, Barrot-Cortes E and Otero-Candelera R: Rivaroxaban for the treatment of venous thromboembolism. A ‘real-life’ perspective in 103 patients. Thromb Res. 134:617–621. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Pesavento R and Iori I: Gruppo Italiano Survey TEV. [Use of rivaroxaban in real-life treatment of venous thromboembolism: Results of the TEV Survey, an Italian epidemiological study]. G Ital Cardiol (Rome). 18:239–246. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR and Hammerstrom J: Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 5:692–699. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A and Dalen JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The worcester DVT study. Arch Intern Med. 151:933–938. 1991.PubMed/NCBI | |
|
Lucena J, Rico A, Vazquez R, Marín R, Martínez C, Salguero M and Miguel L: Pulmonary embolism and sudden-unexpected death: Prospective study on 2477 forensic autopsies performed at the institute of legal medicine in seville. J Forensic Leg Med. 16:196–201. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Heredia V, Ramalho M, Zapparoli M and Semelka RC: Incidence of pulmonary embolism and other chest findings in younger patients using multidetector computed tomography. Acta Radiol. 51:402–406. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kuroki M, Nishino M, Takahashi M, Mori Y, Raptopoulos VD, Boiselle PM, Tamura S and Hatabu H: Incidence of pulmonary embolism in younger versus older patients using CT. J Thorac Imaging. 21:167–171. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Castelli R, Bergamaschini L, Sailis P, Pantaleo G and Porro F: The impact of an aging population on the diagnosis of pulmonary embolism: Comparison of young and elderly patients. Clin Appl Thromb Hemost. 15:65–72. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Roupie AL, Dossier A, Goulenok T, Perozziello A, Papo T and Sacre K: First venous thromboembolism in admitted patients younger than 50 years old. Eur J Intern Med. 34:e18–e20. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Cefalo P, Weinberg I, Hawkins BM, Hariharan P, Okechukwu I, Parry BA, Chang Y, Rosovsky R, Liu SW, Jaff MR and Kabrhel C: A comparison of patients diagnosed with pulmonary embolism who are ≥65 years with patients ≥65 years. Am J Cardiol. 115:681–686. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kreidy R, Salameh P and Waked M: Lower extremity venous thrombosis in patients younger than 50 years of age. Vasc Health Risk Manag. 8:161–167. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF and Folsom AR: Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med. 162:1182–1189. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Theilade J, Winkel BG, Holst AG, Tfelt-Hansen J, Svendsen JH and Haunso S: A nationwide, retrospective analysis of symptoms, comorbidities, medical care and autopsy findings in cases of fatal pulmonary embolism in younger patients. J Thromb Haemost. 8:1723–1729. 2010.PubMed/NCBI View Article : Google Scholar | |
|
White RH, Zhou H and Murin S: Death due to recurrent thromboembolism among younger healthier individuals hospitalized for idiopathic pulmonary embolism. Thromb Haemost. 99:683–690. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Stoeva N, Kirova G, Staneva M, Lekova D, Penev A and Bakalova R: Recognition of unprovoked (idiopathic) pulmonary embolism-Prospective observational study. Respir Med. 135:57–61. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Bruwer G, Limperger V, Kenet G, Klostermeier UC, Shneyder M, Degenhardt F, Finckh U, Heller C, Holzhauer S, Trappe R, et al: Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study. Blood Cells Mol Dis. 62:24–31. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Alhassan S, Pelinescu A, Gandhi V, Naddour M, Singh AC and Bihler E: Clinical presentation and risk factors of venous thromboembolic disease. Crit Care Nurs Q. 40:201–209. 2017.PubMed/NCBI View Article : Google Scholar | |
|
De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A and Leone G: The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S. Haematologica. 91:695–698. 2006.PubMed/NCBI | |
|
Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, Crim MT and Bass EB: Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: A systematic review. JAMA. 301:2472–2485. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Lijfering WM, Middeldorp S, Veeger NJ, Hamulyák K, Prins MH, Büller HR and van der Meer J: Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V leiden and prothrombin G20210A. Circulation. 121:1706–1712. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K and Eichinger S: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 343:457–462. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Eischer L, Gartner V, Schulman S, Kyrle PA and Eichinger S: AUREC-FVIII Investigators. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol. 88:485–490. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, Schönauer V and Kyrle PA: The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost. 1:28–32. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Gjonbrataj E, Kim JN, Gjonbrataj J, Jung HI, Kim HJ and Choi WI: Risk factors associated with provoked pulmonary embolism. Korean J Intern Med. 32:95–101. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Baglin T, Luddington R, Brown K and Baglin C: Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet. 362:523–526. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Palareti G, Legnani C, Cosmi B, Valdré L, Lunghi B, Bernardi F and Coccheri S: Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 108:313–318. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP and Rosendaal FR: Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 293:2352–2361. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Kyrle PA, Rosendaal FR and Eichinger S: Risk assessment for recurrent venous thrombosis. Lancet. 376:2032–2039. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Cannegieter SC and van Hylckama Vlieg A: Venous thrombosis: Understanding the paradoxes of recurrence. J Thromb Haemost. 11:161–169. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ and Kyrle PA: Subcommittees on Control of Anticoagulation and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: Guidance from the SSC of ISTH. J Thromb Haemost. 14:1480–1483. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S and Palareti G: Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: A systematic review. Arch Intern Med. 170:1710–1716. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F and Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:3484–3488. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM and Melton LJ III: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med. 160:761–768. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Pomp ER, Rosendaal FR and Doggen CJ: Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 83:97–102. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Blondon M, Wiggins KL, McKnight B, Psaty BM, Rice KM, Heckbert SR and Smith NL: The association of smoking with venous thrombosis in women. A population-based, case-control study. Thromb Haemost. 109:891–896. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Blix K, Brækkan SK, le Cessie S, Skjeldestad FE, Cannegieter SC and Hansen JB: The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: The tromso study. Eur J Epidemiol. 29:277–284. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kröger K, Moerchel C, Moysidis T and Santosa F: Incidence rate of pulmonary embolism in Germany: Data from the federal statistical office. J Thromb Thrombolysis. 29:349–353. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Green RM, Meyer TJ, Dunn M and Glassroth J: Pulmonary embolism in younger adults. Chest. 101:1507–1511. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Arima M, Kanoh T, Takagi A, Tanimoto K, Oigawa T and Matsuda S: Clinical features of acute pulmonary thromboembolism in younger patients. Circ J. 67:330–333. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kappelman MD, Horvath-Puho E, Sandler RS, Rubin DT, Ullman TA, Pedersen L, Baron JA and Sørensen HT: Thromboembolic risk among danish children and adults with inflammatory bowel diseases: A population-based nationwide study. Gut. 60:937–943. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Lim W: Antiphospholipid syndrome. Hematology. Hematology Am Soc Hematol Educ Program. 2013:675–680. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Spencer FA, Gore JM, Lessard D, Emery C, Pacifico L, Reed G, Gurwitz JH and Goldberg RJ: Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost. 100:780–788. 2008.PubMed/NCBI | |
|
Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R, Rossi R and Verso M: MASTER Investigators. Risk factors for venous thromboembolism in the elderly: Results of the master registry. Blood Coagul Fibrinolysis. 19:663–667. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Wood KE: Major pulmonary embolism: Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 121:877–905. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Mauritz GJ, Marcus JT, Westerhof N, Postmus PE and Vonk-Noordegraaf A: Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart. 97:473–478. 2011.PubMed/NCBI View Article : Google Scholar | |
|
McIntyre KM and Sasahara AA: The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol. 28:288–294. 1971.PubMed/NCBI View Article : Google Scholar | |
|
Lankhaar JW, Westerhof N, Faes TJ, Marques KM, Marcus JT, Postmus PE and Vonk-Noordegraaf A: Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol. 291:H1731–H1737. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Lankeit M, Jimenez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P and Konstantinides S: Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: A prospective validation study. Circulation. 124:2716–2724. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Mehta NJ, Jani K and Khan IA: Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J. 145:821–825. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Burrowes KS, Clark AR and Tawhai MH: Blood flow redistribution and ventilation-perfusion mismatch during embolic pulmonary arterial occlusion. Pulm Circ. 1:365–376. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Gisselbrecht M, Diehl JL, Meyer G, Collignon MA and Sors H: Clinical presentation and results of thrombolytic therapy in older patients with massive pulmonary embolism: A comparison with non-elderly patients. J Am Geriatr Soc. 44:189–193. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Timmons S, Kingston M, Hussain M, Kelly H and Liston R: Pulmonary embolism: Differences in presentation between older and younger patients. Age Ageing. 32:601–605. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Parenti NBA, Bonarelli S and Fanciulli A: Pulmonary embolism in younger adults: Clinical presentation and comparison of two scoring systems used to estimate pretest probability of disease in the emergency department. Ann Emerg Med. 44(36)2004. | |
|
Witt DM, Clark NP, Kaatz S, Schnurr T and Ansell JE: Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 41:187–205. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A and ten Cate JW: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 339:441–445. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Columbus Investigtors. Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH and Baildon R: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 337:657–662. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, et al: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 11(21)2013.PubMed/NCBI View Article : Google Scholar | |
|
Lopez-Jimenez L, Montero M, Gonzalez-Fajardo JA, Arcelus JI, Suárez C, Lobo JL, Monreal M and RIETE Investigators: Venous thromboembolism in very elderly patients: Findings from a prospective registry (RIETE). Haematologica. 91:1046–1051. 2006.PubMed/NCBI | |
|
Lim W, Dentali F, Eikelboom JW and Crowther MA: Meta-Analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 144:673–684. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB and Tracy RP: Venous thrombosis in the elderly: More questions than answers. Blood. 110:3097–3101. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, et al: Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 369:799–808. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Hokusai-VTE Investigators. Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, et al: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369:1406–1415. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Johnson M, Mardekian J, Phatak H, Thompson J and Cohen AT: Apixaban reduces hospitalizations in patients with venous thromboembolism: An analysis of the apixaban for the initial management of pulmonary embolism and deep-vein thrombosis as first-line therapy (AMPLIFY) trial. J Am Heart Assoc. 4(12)2015.PubMed/NCBI View Article : Google Scholar | |
|
van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA and Huisman MV: Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 12:320–328. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kvasnicka T, Malikova I, Zenahlikova Z, Kettnerova K, Brzezkova R, Zima T, Ulrych J, Briza J, Netuka I and Kvasnicka J: Rivaroxaban-metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 18:636–642. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT and Allon M: Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 20:912–921. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al: The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 39:1330–1393. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, et al: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358:2765–2775. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al: Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 377:1319–1330. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, et al: Risk for venous thromboembolism recurrence among rivaroxaban-treated patients who continued versus discontinued therapy: Analyses among patients with VTE. Clin Ther. 39:1396–1408. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Coleman CI, Bunz TJ and Turpie AGG: Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Thromb Haemost. 117:1841–1847. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Larsen TB, Skjøth F, Kjaeldgaard JN, Lip GYH, Nielsen PB and Sogaard M: Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: A propensity-matched nationwide cohort study. Lancet Haematol. 4:e237–e244. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E and Turpie AG: Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study. Lancet Haematol. 3:e12–e21. 2016.PubMed/NCBI View Article : Google Scholar | |
|
van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M and Lensing AW: Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin. 30:829–837. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L and Nutescu EA: Cost-Effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ. 17:52–64. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Merli GJ, Hollander JE, Lefebvre P, Laliberté F, Raut MK, Germain G, Bookhart B and Pollack CV: Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. J Med Econ. 19:84–90. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR and Hernandez J: Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 12:459–468. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, et al: Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 370:1402–1411. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ, Patel N, Raman F, Arora G, Al Solaiman F, et al: Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses. Int J Cardiol. 225:128–139. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, et al: Effect of a retrievable inferior vena cava filter plus anticoagulation vs. anticoagulation alone on risk of recurrent pulmonary embolism: A randomized clinical trial. JAMA. 313:1627–1635. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Gnoth MJ, Buetehorn U, Muenster U, Schwarz T and Sandmann S: In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 338:372–380. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Song ZK, Cao H, Wei H, Wei Q, Tang M, Yang S, Liu Y and Qin L: Current status of rivaroxaban in elderly patients with pulmonary embolism (Review). Exp Ther Med. 19:2817–2825. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Li SJ, Tu YM, Zhou CS, Zhang LH and Liu ZH: Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol. 20:212–217. 2016.PubMed/NCBI View Article : Google Scholar |
